|
BRIEF: Recent Teva acquisition reports profit: The company said its acquisition by Teva will be closed following the spin off of its drug delivery...
(Globes Via Acquire Media NewsEdge) May 12--Bentley Pharmaceuticals Inc. (NYSE: BNT), which was recently acquired by Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) for $360 million, has published its financial report for the first quarter of 2008. The company posted $40 million revenue for the quarter, of which $36.6 million was generated by its specialty generics segment, which will be transferred to Teva once the acquisition is closed, and the rest by its drug delivery activity. Net profit totaled $1.1 million, with Bentley reporting a profit of $3.2 million on its specialty generics segment and a $2.1 million loss on its drug delivery activity.
Bentley said its acquisition by Teva would be closed following the spin off of its drug delivery activity as a new company, CPEX Pharmaceuticals.
To see more of the Globes or to subscribe to the newspaper, go to http://www.globes.co.il.
Copyright (c) 2008, Globes, Tel Aviv, Israel
Distributed by McClatchy-Tribune Information Services.
For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
[ Back To TMCnet.com's Homepage ]
|